Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.44), $0.10 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $0.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.